Editorial: Current and Emerging Therapeutics in AD

Sabbagh, Marwan N.; Decourt, Boris

doi:10.2174/156720501404170217182758

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, behavioral and psychological symptoms of dementia (BPSD) afflict the vast majority of patients, especially those with Alzheimer’s disease (AD) [ 2 ]. AD represents 60–80% of all dementia types [ 3 ] and is the sixth leading cause of death in the United States [ 4 ]. The presence of extracellular senile plaques of insoluble β-amyloid peptide (Aβ) and neurofibrillary tangles composed of phosphorylated tau protein (P-tau) in neuronal cytoplasm constitute the hallmarks of this neurological condition [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Technological Solutions for Diagnosis, Management and Treatment of Alzheimer’s Disease-Related Symptoms: A Structured Review of the Recent Scientific Literature

Cammisuli

Cipriani

Castelnuovo

2022

IJERPH

View full text Add to dashboard Cite

In people with Alzheimer’s disease (PwAD), there is a need for specific tools for the timely diagnosis, management, and treatment of symptoms. New technological solutions, including digital devices, application programs (apps), sensors and virtual reality, represent promising possibilities for objective and reliable assessment, monitoring and intervention strategies in this field. Our structured review presents an up-to-date summary of the technological solutions for the (i) diagnosis, (ii) management and (iii) treatment of AD-related symptoms. To this end, we searched electronic databases (i.e., PubMed, Web of Science, and Cochrane Library) for studies published over the last 10 years. Two authors of the review extracted data of interest. A total of eight manuscripts were included. In the last decade, a series of technological solutions across AD stages have been proposed. These include: (i) innovative strategies for the early detection of deficits in finger dexterity, visuo-spatial abilities (including spatial navigation), divided attention and instrumental autonomy; (ii) tools to activate the patient’s responsiveness in terms of alertness and mood improvement; and (iii) useful interventions for retrieving memories, increasing body movements and improving spatial cognition. Methodological limitations, mainly pertaining to the paucity of randomized controlled trials and comprehensive assessments, were observed. Advances in technology currently provide the potential for designing innovative methods for evaluating, controlling and handling AD-related symptoms. The co-creation of technological solutions with all stakeholders represents the best way to design effective strategies for PwAD.

show abstract

Section: Introductionmentioning

confidence: 99%

Technological Solutions for Diagnosis, Management and Treatment of Alzheimer’s Disease-Related Symptoms: A Structured Review of the Recent Scientific Literature

Cammisuli

Cipriani

Castelnuovo

2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Alzheimer’s disease (AD), a disorder characterized by the abnormal accumulation of misfolded protein aggregates and subsequent neuronal death, is the leading cause of dementia worldwide [ 1 , 2 , 3 , 4 , 5 , 6 ]. Due to the lack of efficient therapeutics, AD is yet untreatable [ 7 , 8 ]. Therefore, AD patients have to face progressive mental and physical deterioration [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Syndecan-3 as a Novel Biomarker in Alzheimer’s Disease

Hudák¹,

Letoha

Vízler

et al. 2022

IJMS

View full text Add to dashboard Cite

Early diagnosis of Alzheimer’s disease (AD) is of paramount importance in preserving the patient’s mental and physical health in a fairly manageable condition for a longer period. Reliable AD detection requires novel biomarkers indicating central nervous system (CNS) degeneration in the periphery. Members of the syndecan family of transmembrane proteoglycans are emerging new targets in inflammatory and neurodegenerative disorders. Reviewing the growing scientific evidence on the involvement of syndecans in the pathomechanism of AD, we analyzed the expression of the neuronal syndecan, syndecan-3 (SDC3), in experimental models of neurodegeneration. Initial in vitro studies showed that prolonged treatment of tumor necrosis factor-alpha (TNF-α) increases SDC3 expression in model neuronal and brain microvascular endothelial cell lines. In vivo studies revealed elevated concentrations of TNF-α in the blood and brain of APPSWE-Tau transgenic mice, along with increased SDC3 concentration in the brain and the liver. Primary brain endothelial cells and peripheral blood monocytes isolated from APPSWE-Tau mice exhibited increased SDC3 expression than wild-type controls. SDC3 expression of blood-derived monocytes showed a positive correlation with amyloid plaque load in the brain, demonstrating that SDC3 on monocytes is a good indicator of amyloid pathology in the brain. Given the well-established role of blood tests, the SDC3 expression of monocytes could serve as a novel biomarker for early AD detection.

show abstract

Editorial: Current and Emerging Therapeutics in AD

Cited by 2 publications

References 15 publications

Technological Solutions for Diagnosis, Management and Treatment of Alzheimer’s Disease-Related Symptoms: A Structured Review of the Recent Scientific Literature

Technological Solutions for Diagnosis, Management and Treatment of Alzheimer’s Disease-Related Symptoms: A Structured Review of the Recent Scientific Literature

Syndecan-3 as a Novel Biomarker in Alzheimer’s Disease

Contact Info

Product

Resources

About